|
USP9X expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.23709999811217E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.45259999998027E-06 |
| Normal-vs-Stage2 |
3.764500E-03 |
| Normal-vs-Stage3 |
8.96239999992332E-08 |
| Normal-vs-Stage4 |
1.12519999984073E-08 |
| Stage1-vs-Stage2 |
4.402000E-01 |
| Stage1-vs-Stage3 |
1.008390E-01 |
| Stage1-vs-Stage4 |
9.895700E-03 |
| Stage2-vs-Stage3 |
6.401800E-02 |
| Stage2-vs-Stage4 |
5.395900E-03 |
| Stage3-vs-Stage4 |
2.014800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
6.5283999983734E-08 |
| Normal-vs-AfricanAmerican |
3.944200E-02 |
| Normal-vs-Asian |
6.40399999999319E-05 |
| Caucasian-vs-AfricanAmerican |
1.732170E-01 |
| Caucasian-vs-Asian |
8.989000E-01 |
| AfricanAmerican-vs-Asian |
2.377600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.50549572808245E-11 |
| Normal-vs-Female |
4.6272999999486E-06 |
| Male-vs-Female |
1.574060E-04 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.522899999997E-05 |
| Normal-vs-Age(41-60Yrs) |
1.78530000005672E-07 |
| Normal-vs-Age(61-80Yrs) |
5.1884999996421E-07 |
| Normal-vs-Age(81-100Yrs) |
5.602700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.191800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.073200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.872800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.209200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.897000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.330200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.230300E-02 |
| Classical-VS-Follicular |
2.922400E-01 |
| Classical-VS-Other |
7.540300E-02 |
| Classical-VS-Normal |
2.76300000001672E-06 |
| Tall-VS-Follicular |
2.840200E-01 |
| Tall-VS-Other |
4.178600E-01 |
| Tall-VS-Normal |
1.59244999999864E-05 |
| Follicular-VS-Other |
1.983560E-01 |
| Follicular-VS-Normal |
2.10179999999838E-05 |
| Other-VS-Normal |
1.297310E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.34880000005155E-07 |
| Normal-vs-N1 |
2.22750000000715E-07 |
| N0-vs-N1 |
1.349150E-01 |
|
|
